Therapeutic compositions comprising deuterated or partially deuterated N,N-dimethyltryptamine compounds

By using a composition of N,N-dimethyltryptamine and its deuterated analog, pharmacokinetic characteristics are adjusted, and the problems of short duration of DMT treatment and toxic accumulation are solved, achieving flexible psychotherapy and longer Metabolic half-life.

CN114096246BActive Publication Date: 2024-11-22CYBIN UK LTD
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202080050439.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2019-06-03
Filing Date
2020-06-02
Publication Date
2024-11-22
Estimated Expiration
2040-06-02

AI Technical Summary

Technical Problem

Traditional N,N-dimethyltryptamine (DMT) as hallucinogens has short-acting limitations in the treatment of mental disorders and has a risk of toxicity accumulation in patients with malnutrition. Existing prolongation therapy is complex and inflexible.

Method used

By providing compositions containing N,N-dimethyltryptamine and its deuterated analogues, pharmacokinetic characteristics are adjusted using kinetic isotope effects, fine-tune single dose administration, prolong treatment duration, and reduce clinical complexity increase treatment flexibility.

Benefits of technology

The fine-tuning of DMT treatment duration without relying on infusion regimens or monoamine oxidase inhibitors is achieved, reducing clinical complexity, improving therapeutic flexibility, and significantly extending the metabolic half-life of the compound through the degree of deuteratedness.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN114096246B_ABST
    Figure CN114096246B_ABST
Patent Text Reader

Abstract

The present invention relates to compositions comprising N,N-dimethyltryptamine, deuterated N,N-dimethyltryptamine and / or partially deuterated N,N-dimethyltryptamine. In particular, the present invention relates to a combination comprising N,N-dimethyltryptamine and 2% or more by weight of one or more deuterated N,N-dimethyltryptamine compounds selected from α,α-dideuterated-N,N-dimethyltryptamine and α,α,β,β-tetradeuterated-N,N-dimethyltryptamine. Additional and alternative compositions of the present invention comprise a combination of N,N-dimethyltryptamine and 2% or more by weight of one or more partially deuterated N,N-dimethyltryptamine compounds selected from α,β,β-trideuterated-N,N-dimethyltryptamine, α,β-dideuterated-N,N-dimethyltryptamine and α-deuterated-N,N-dimethyltryptamine. Also provided are methods of synthesizing the compositions of the invention and methods of using the compositions described herein to treat psychiatric or cognitive disorders such as major depressive disorder.
Need to check novelty before this filing date? Find Prior Art

Description

Field of the Invention

[0001] The present invention relates to a composition comprising two or more compounds selected from N,N-dimethyltryptamine, deuterated N,N-dimethyltryptamine and partially deuterated N,N-dimethyltryptamine.

[0002] In particular, the present invention relates to a composition comprising a combination of N,N-dimethyltryptamine and 2% or more by weight of one or more deuterated N,N-dimethyltryptamine compounds, wherein the deuterated N,N-dimethyltryptamine compound is selected from α,α-dideutero-N,N-dimethyltryptamine and α,α,β,β-tetradeutero-N,N-dimethyltryptamine. Additional and alternative compositions of the present invention comprise a combination of N,N-dimethyltryptamine and 2% or more by weight of one or more partially deuterated N,N-dimethyltryptamine compounds, wherein the partially deuterated N,N-dimethyltryptamine compound is selected from α,β,β-trideutero-N,N-dimethyltryptamine, α,β-dideutero-N,N-dimethyltryptamine and α-deutero-N,N-dimethyltryptamine. Methods for synthesizing the compositions of the present invention are also provided, as well as methods for using such compositions to treat mental disorders or mental cognitive disorders (such as major depressive disorder). Background of the Invention

[0004] Traditional hallucinogens have shown preclinical and clinical promise in the treatment of psychiatric disorders (Carhart-Harris and Goodwin (2017), The Therapeutic Potential of Psychedelic Drugs: Past, Present and Future, Neuropsychopharmacology 42, 2105-2113). In particular, in a randomized double-blind study, psilocybin has demonstrated significant improvements in a range of depression and anxiety rating scales (Griffiths et al. (2016), Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomised double-blind trial, Journal of Psychopharmacology 30 (12), 1181-1197).

[0005] N, N-dimethyltryptamine (DMT) is also understood to have therapeutic value as a short-acting hallucinogen, however its duration of action (less than 20 minutes) is so short that it limits effective therapy. Administration protocols have been developed to prolong the immersive hallucinogenic experience of DMT (Gallimore and Strassman (2016), A model for the application of target-controlled intravenous infusion for a prolonged immersive DMT psychedelic experience, Frontiers in Pharmacology, 7: 211). However, these protocols have the risk of toxic accumulation in patients with poor DMT metabolism (for further discussion, see Strassman et al. (1994), Dose response study of N, N-dimethyltryptamine in humans, Arch Gen Psychiatry 51, 85).

[0006] α,α,β,β-tetradeuterated-N,N-dimethyltryptamine is known to exhibit a kinetic isotope effect that confers significant differences in its in vivo pharmacokinetic profile compared to N,N-dimethyltryptamine. 3 The substitution of deuterium for hydrogen at the carbon center produces a "kinetic isotope effect" due to the difference in bond strength between the CH and CD bonds. First demonstrated in 1982 (Barker et al. (1982), Comparison of the brain levels of N,N-dimethyltryptamine and α,α,β,β-tetradeutero-N,N-dimethyltryptamine following intraperitoneal injection, Biochemical Pharmacology, 31(15), 2513-2516), the half-life of α,α,β,β-tetradeutero-N,N-dimethyltryptamine in the rodent brain suggests that administration of α,α,β,β-tetradeutero-N,N-dimethyltryptamine alone will maintain patients in the DMT space for longer periods of time than is therapeutically necessary.

[0007] Brief description of the invention

[0008] The present invention is based in part on the ability to apply the knowledge of the kinetic isotope effect exhibited by α,α,β,β-tetradeuterated-N,N-dimethyltryptamine so as to controllably improve the pharmacokinetic characteristics of N,N-dimethyltryptamine, thereby allowing more flexible therapeutic applications. In particular, by providing a separate drug substance composition comprising a mixture of N,N-dimethyltryptamine and deuterated N,N-dimethyltryptamine analogs, in particular N,N-dimethyltryptamine containing at least one deuterium atom at the α position (i.e., the carbon atom to which the dimethylamino moiety is attached), and according to certain embodiments, N,N-dimethyltryptamine containing one or two deuterium atoms at the β position, the present invention provides compositions and methods that can finely adjust single-dose administration to maintain a patient's complete dissociation from the outside world (referred to herein as "DMT space") for a therapeutically optimized duration without relying on an infusion regimen or a combination therapy with a monoamine oxidase inhibitor in the clinic. The present invention provides a clinically applicable solution that reduces clinical complexity and increases clinical flexibility in administering DMT-assisted psychotherapy.

[0009] In addition, we have observed a quantifiable relationship between the degree of deuteration (represented by the H:D ratio of the feed reductant in the synthetic methods disclosed herein) and the effect on enhancing the metabolic half-life of the parent compound. This technical effect can be used to quantifiably improve the precision with which compositions containing multiple N,N-dimethyltryptamine compounds (i.e., containing more than one type of compound selected from the following: N,N-dimethyltryptamine and deuterated analogs thereof, particularly those deuterated at the α position and optionally at the β position, or pharmaceutically acceptable salts of these) can be prepared.

[0010] Thus, from a first aspect, the present invention provides a composition comprising two or more compounds selected from the group consisting of N,N-dimethyltryptamine, α,α-dideutero-N,N-dimethyltryptamine compounds, α-protonated (protio), α-deutero-N,N-dimethyltryptamine compounds and pharmaceutically acceptable salts of these compounds.

[0011] Viewed from a second aspect, the invention provides a composition obtainable by reducing 2-(3-indolyl)-N,N-dimethylglyoxalamide with a reducing agent consisting essentially of up to 90 mol % lithium aluminum hydride and 10 mol % or more lithium aluminum deuteride.

[0012] Viewed from a third aspect, the invention provides a composition obtainable by reducing 2-(3-indolyl)-N,N-dimethylacetamide with a reducing agent consisting essentially of up to 90 mol % by weight of lithium aluminum hydride and 10 mol % or more of lithium aluminum deuteride.

[0013] Viewed from a fourth aspect, the invention provides a pharmaceutical composition comprising a composition as defined in any one of the first to third aspects in combination with a pharmaceutically acceptable excipient.

[0014] Viewed from a fifth aspect, the invention provides a composition as defined according to any one of the first to fourth aspects, for use in therapy.

[0015] From a sixth aspect, the present invention provides a composition as defined in any one of the first to fourth aspects for use in a method of treating a psychotic cognitive disorder in a patient.

[0016] Viewed from a seventh aspect, the present invention provides a method for treating a psychotic cognitive disorder, comprising administering to a patient in need thereof a composition as defined in any one of the first to fourth aspects.

[0017] Viewed from an eighth aspect, the present invention provides use of a composition as defined in any one of aspects 1 to 4 in the preparation of a medicament for use in a method of treating a psychotic cognitive disorder in a patient.

[0018] Viewed from a ninth aspect, the present invention provides a method for preparing a composition according to any one of the first to third aspects of the present invention, comprising contacting 2-(3-indolyl)-N,N-dimethylglyoxylamide and / or 2-(3-indolyl)-N,N-dimethylacetamide with a reducing agent, the reducing agent consisting essentially of up to 90 mol % of lithium aluminum hydride and 10 mol % or more of lithium aluminum deuteride.

[0019] From a tenth aspect, the present invention provides a compound selected from α,β,β-trideuterated-N,N-dimethyltryptamine, α,α,β-trideuterated-N,N-dimethyltryptamine, α,β-dideuterated-N,N-dimethyltryptamine and α-deuterated-N,N-dimethyltryptamine.

[0020] Other aspects and embodiments of the invention will be apparent from the following discussion. BRIEF DESCRIPTION OF THE DRAWINGS

[0022] Figure 1 Depicted are the predicted pharmacokinetic properties of partially deuterated DMT compared to DMT and fully deuterated DMT. Predicted A) plasma concentrations and B) brain tissue concentrations show an extended half-life for partially deuterated DMT. The hashed region depicts the effect site concentration (>60 ng / mL) experienced as complete dissociation from the outside world (called "DMT space").

[0023] Figure 2Graphs showing the calculated in vitro half-lives of DMT and the six deuterium-containing compositions described in Example 4. A) Linear regression analysis. The r2 value for the half-life was 0.754; the slope was found to be significantly different from zero, p = 0.01. B) Half-lives of the deuterated analogs, as percent change relative to (undeuterated) DMT (dashed line).

[0024] Figure 3 is the in vitro intrinsic clearance of DMT and the six deuterium-containing compositions described in Example 4. A) Linear regression analysis. r of intrinsic clearance 2 The value is 0.7648; where the slope was found to be significantly different from zero, p = 0.01. B) Intrinsic clearance of the deuterated analogs, presented as percent change relative to (undeuterated) DMT (dashed line). DETAILED DESCRIPTION OF THE INVENTION

[0026] Throughout the specification, one or more aspects of the present invention may be combined with one or more features described in the specification to define different embodiments of the present invention.

[0027] Unless the context implies otherwise, reference herein to a singular noun includes the plural noun and vice versa.

[0028] Throughout the specification, the word "comprise" or variations such as "comprises" or "comprising" will be understood to imply the inclusion of stated elements, integers or steps, or groups of elements, integers or steps, but not the exclusion of any other elements, integers or steps, or groups of elements, integers or steps.

[0029] The present invention provides a composition comprising two or more compounds selected from the group consisting of N,N-dimethyltryptamine, α,α-dideutero-N,N-dimethyltryptamine compounds, α-protonated, α-deutero-N,N-dimethyltryptamine compounds and pharmaceutically acceptable salts of these compounds.

[0030] Deuterium atoms are hydrogen atoms with an extra neutron.

[0031] In this document, the terms α,α-dideutero-N,N-dimethyltryptamine compounds and α-protonated, α-deutero-N,N-dimethyltryptamine compounds are often referred to as deuterated (or fully deuterated) N,N-dimethyltryptamine and partially deuterated N,N-dimethyltryptamine, respectively. Thus, deuterated (or fully deuterated) N,N-dimethyltryptamine strictly refers to N,N-dimethyltryptamine compounds in which both protons at the α position are replaced by deuterium atoms. The term partially deuterated N,N-dimethyltryptamine strictly refers to N,N-dimethyltryptamine compounds in which one of the two protons at the α position is replaced by a deuterium atom. The deuterated N,N-dimethyltryptamine compound of the present invention is any N,N-dimethyltryptamine compound substituted with two deuterium atoms at the α position, and the partially deuterated N,N-dimethyltryptamine compound of the present invention is any N,N-dimethyltryptamine compound having one hydrogen atom and one deuterium atom at the α position.

[0032] Therefore, the present invention provides a composition comprising two or more compounds selected from N,N-dimethyltryptamine, deuterated N,N-dimethyltryptamine and partially deuterated N,N-dimethyltryptamine, that is, a composition comprising a combination of N,N-dimethyltryptamine and one or more deuterated or partially deuterated N,N-dimethyltryptamine compounds.

[0033] N,N-dimethyltryptamine and all its deuterated analogs freely form addition salts with anionic counterions. Throughout the specification, N,N-dimethyltryptamine compounds (particularly N,N-dimethyltryptamine, α,α-dideutero-N,N-dimethyltryptamine compounds and α-protonated, α-deutero-N,N-dimethyltryptamine compounds) also refer to any pharmaceutically acceptable salts, such as fumarate.

[0034] Typically, acidic agents can be used to prepare salts of N,N-dimethyltryptamine compounds, particularly pharmaceutically acceptable salts. Examples of suitable acidic agents are selected from fumaric acid, hydrochloric acid, tartaric acid, citric acid, hydrobromic acid, sulfuric acid, phosphoric acid, acetic acid, maleic acid, lactic acid, tartaric acid and gluconic acid. Typically, when in the form of a salt, the N,N-dimethyltryptamine compound used in the composition of the present invention or otherwise according to various aspects of the present invention and embodiments thereof (particularly as a compound of the present invention) is a fumarate, hydrochloride, tartrate or citrate, particularly a fumarate.

[0035] Thus, the compounds present in the compositions of the first aspect of the invention and indeed those of the second and third (and other, as appropriate) aspects of the invention may be present as N,N-dimethyltryptamine compounds in free base or salt form (such as the salts described herein), in particular N,N-dimethyltryptamine or deuterated or partially deuterated N,N-dimethyltryptamine compounds as defined herein, optionally in the presence of solvates thereof (e.g. hydrates).

[0036] According to a specific embodiment of the invention, α, α-dideuterated-N, N-dimethyltryptamine compounds (fully deuterated compounds) contain 0, 1 or 2 deuterium atoms in the β position, but are identical to the compound N, N-dimethyltryptamine except that 2, 3 or 4 deuterium atoms are present. According to these and other specific embodiments of the invention, α-protonated, α-deuterated-N, N-dimethyltryptamine compounds (partially deuterated compounds) may also contain 0, 1 or 2 deuterium atoms in the β position, but are identical to the compound N, N-dimethyltryptamine except that 1, 2 or 3 deuterium atoms are present. Six fully deuterated and partially deuterated compounds according to these specific embodiments of the invention are depicted in the following table:

[0037]

[0038]

[0039] In a preferred embodiment of the first aspect, the composition comprises 2% or more by weight of one or more deuterated or partially deuterated N,N-dimethyltryptamine compounds. In a preferred embodiment of the first aspect, the composition comprises 5% or more by weight of one or more deuterated or partially deuterated N,N-dimethyltryptamine compounds. In a preferred embodiment of the first aspect, the composition comprises 10% or more by weight of one or more deuterated or partially deuterated N,N-dimethyltryptamine compounds. In a preferred embodiment of the first aspect, the composition comprises 15% or more by weight of one or more deuterated or partially deuterated N,N-dimethyltryptamine compounds. In a preferred embodiment of the first aspect, the composition comprises 20% or more by weight of one or more deuterated or partially deuterated N,N-dimethyltryptamine compounds. In a preferred embodiment of the first aspect, the composition comprises 25% or more by weight of one or more deuterated or partially deuterated N,N-dimethyltryptamine compounds. In a preferred embodiment of the first aspect, the composition comprises 30% or more by weight of one or more deuterated or partially deuterated N,N-dimethyltryptamine compounds. In a preferred embodiment of the first aspect, the composition comprises 50% or more by weight of one or more deuterated or partially deuterated N,N-dimethyltryptamine compounds. In a preferred embodiment of the first aspect, the composition comprises 60% or more by weight of one or more deuterated or partially deuterated N,N-dimethyltryptamine compounds. In a preferred embodiment of the first aspect, the composition comprises 75% or more by weight of one or more deuterated or partially deuterated N,N-dimethyltryptamine compounds. In a preferred embodiment of the first aspect, the composition comprises up to 90% by weight of one or more deuterated or partially deuterated N,N-dimethyltryptamine compounds. In a preferred embodiment of the first aspect, the composition comprises up to 95% by weight of one or more deuterated or partially deuterated N,N-dimethyltryptamine compounds. In a preferred embodiment of the first aspect, the composition comprises up to 96% by weight of one or more deuterated or partially deuterated N,N-dimethyltryptamine compounds. In a preferred embodiment of the first aspect, the composition comprises up to 97% by weight of one or more deuterated or partially deuterated N,N-dimethyltryptamine compounds. In a preferred embodiment of the first aspect, the composition comprises up to 98% by weight of one or more deuterated or partially deuterated N,N-dimethyltryptamine compounds.

[0040] % to 96%, 15% to 97%, 15% to 98%; 20% to 90%, 20% to 95%, 20% to 96%, 20% to 97%, 20% to 98% by weight. or 75% to 90%, 75% to 95%, 75% to 96%, 75% to 97%, 75% to 98% of one or more deuterated or partially deuterated N,N-dimethyltryptamine compounds.

[0041] In an embodiment of the first aspect, the composition comprises a combination of N,N-dimethyltryptamine and one or more deuterated N,N-dimethyltryptamine compounds selected from the group consisting of α,α-dideutero-N,N-dimethyltryptamine, α,α,β-trideutero-N,N-dimethyltryptamine and α,α,β,β-tetradeutero-N,N-dimethyltryptamine, for example, a combination of N,N-dimethyltryptamine and α,α-dideutero-N,N-dimethyltryptamine, a combination of N,N-dimethyltryptamine and α,α,β,β-tetradeutero-N,N-dimethyltryptamine, or a combination of N,N-dimethyltryptamine, α,α-dideutero-N,N-dimethyltryptamine and α,α-dideutero-N,N-dimethyltryptamine.

[0042] In a preferred embodiment of the first aspect, the composition comprises a combination of N,N-dimethyltryptamine and 2% or more by weight of one or more deuterated N,N-dimethyltryptamine compounds selected from α,α-dideutero-N,N-dimethyltryptamine and α,α,β,β-tetradeutero-N,N-dimethyltryptamine.

[0043] In other embodiments of the first aspect, the composition comprises a combination of N,N-dimethyltryptamine and 2% or more by weight of one or more deuterated N,N-dimethyltryptamine compounds selected from the group consisting of α,α-dideutero-N,N-dimethyltryptamine, α,α,β-trideutero-N,N-dimethyltryptamine and α,α,β,β-tetradeutero-N,N-dimethyltryptamine.

[0044] In a preferred embodiment of the first aspect, the composition comprises 2% by weight or more of α,α,β,β-tetradeuterated-N,N-dimethyltryptamine.

[0045] In a preferred embodiment of the first aspect, the composition comprises 2% by weight or more of α,α-dideutero-N,N-dimethyltryptamine.

[0046] In certain embodiments of the first aspect, the composition comprises 2% by weight or more of α,α,β,β-tetradeutero-N,N-dimethyltryptamine and 2% by weight or more of α,α-dideutero-N,N-dimethyltryptamine.

[0047] It will be understood that wherever a composition contains 2% or more by weight of one or more deuterated N,N-dimethyltryptamine compounds, such a composition may contain up to 95% by weight of one or more deuterated N,N-dimethyltryptamine compounds, or up to 96% by weight, up to 97% by weight, or up to 98% by weight.

[0048] In a preferred embodiment of the first aspect, the composition comprises or further comprises, for example, further comprises one or more partially deuterated N,N-dimethyltryptamine compounds selected from the following: α,β,β-trideuterated-N,N-dimethyltryptamine, α,β-dideuterated-N,N-dimethyltryptamine and α-deuterated-N,N-dimethyltryptamine. Preferably, the partially deuterated N,N-dimethyltryptamine compound is α-deuterated-N,N-dimethyltryptamine.

[0049] In a preferred embodiment, the one or more partially deuterated N,N-dimethyltryptamine compounds comprise up to 50% by weight of the total composition.

[0050] According to other preferred embodiments of the first aspect of the present invention, the composition comprises up to 50% by weight (based on the total weight of the composition) of one or more compounds selected from the following: α, α-dideutero-N, N-dimethyltryptamine compounds, α-protonated, α-deutero-N, N-dimethyltryptamine compounds and pharmaceutically acceptable salts thereof. It will be understood that in such embodiments, such compositions may comprise 2% or more, such as 5% or more, 10% or more, 15% or more, 20% or more, 25% or more or 30% or more (based on the total composition) of the one or more compounds.

[0051] Typically, the compositions of the invention comprise N,N-dimethyltryptamine.

[0052] According to a specific embodiment, the composition of the present invention, including all embodiments described herein, including but not limited to those comprising N,N-dimethyltryptamine, consists essentially of two or more N,N-dimethyltryptamine compounds (i.e., compounds selected from N,N-dimethyltryptamine and deuterated analogs thereof (particularly those deuterated at the α and optional β positions), or pharmaceutically acceptable salts of these). A composition consisting essentially of two or more N,N-dimethyltryptamine compounds means that the composition may contain additional components (in addition to the N,N-dimethyltryptamine compound), but the presence of these additional components will not substantially affect the basic characteristics of the composition. In particular, a composition consisting essentially of N,N-dimethyltryptamine compounds will not contain substantial amounts of other pharmaceutically active substances (i.e., substantial amounts of other drug substances).

[0053] Even more typically, the compositions of the present invention, including all embodiments described herein, including but not limited to those comprising N,N-dimethyltryptamine, are composed of two or more N,N-dimethyltryptamine compounds.

[0054] The composition of the present invention may contain 2% to 98% by weight of N,N-dimethyltryptamine, and preferably contains 5% to 95% by weight of N,N-dimethyltryptamine. Preferred compositions of the present invention contain 10% to 90% by weight of N,N-dimethyltryptamine, or 15% to 85% by weight of N,N-dimethyltryptamine, or 20% to 80% by weight of N,N-dimethyltryptamine, or 25% to 75% by weight of N,N-dimethyltryptamine, or 30% to 70% by weight of N,N-dimethyltryptamine, or 40% to 60% by weight of N,N-dimethyltryptamine.

[0055] The composition of the present invention preferably comprises 5 to 95% by weight of a deuterated N,N-dimethyltryptamine compound selected from α,α-dideutero-N,N-dimethyltryptamine and α,α,β,β-tetradeutero-N,N-dimethyltryptamine.

[0056] A second aspect of the invention provides a composition obtainable by reducing 2-(3-indolyl)-N,N-dimethylglyoxylamide with a reducing agent, the reducing agent being essentially composed of: up to 90 mol% of lithium aluminum hydride and 10 mol% or more of lithium aluminum deuteride; and, a third aspect provides a composition obtainable by reducing 2-(3-indolyl)-N,N-dimethylacetamide with a reducing agent, the reducing agent being essentially composed of up to 90 mol% of lithium aluminum hydride and 10 mol% or more of lithium aluminum deuteride. In both aspects, the reducing agent can be dissolved or suspended in a liquid medium. Typically, due to its strong reactivity with water and protective solvents such as alcohols, although it can be obtained in solid (powder) form, lithium aluminum hydride (or lithium aluminum deuteride) is typically operated under an inert atmosphere, typically in a dry aprotic solvent such as ether. Technicians are familiar with these precautions and appropriate protocols.

[0057] It will be appreciated that the invention thus provides a composition obtainable by reducing a composition comprising one or more of 2-(3-indolyl)-N,N-dimethylglyoxylamide and 2-(3-indolyl)-N,N-dimethylacetamide with a reducing agent consisting essentially of up to 90 mole % of lithium aluminium hydride and 10 mole % or more of lithium aluminium deuteride, optionally dissolved or suspended in a liquid medium. The invention also provides a composition obtained by such reduction, or more generally, a composition obtained by reduction according to the second or third aspect of the invention.

[0058] It will also be appreciated that the amounts of N,N-dimethyltryptamine compounds described herein with specific reference to the composition of the first aspect of the invention may apply mutatis mutandis to the compositions of the second and third aspects of the invention.

[0059] Preferably, the reducing agent described herein, for example according to the second, third and ninth aspects of the invention, and as described in the preceding paragraph, consists essentially of 85 mol% lithium aluminum hydride and 15 mol% lithium aluminum deuteride, or consists essentially of 80 mol% lithium aluminum hydride and 20 mol% lithium aluminum deuteride, or consists essentially of 25 mol% lithium aluminum hydride and 75 mol% lithium aluminum deuteride, or consists essentially of 30 mol% lithium aluminum hydride and 70 mol% lithium aluminum deuteride, or consists essentially of 65 mol% lithium aluminum hydride and 35 mol% lithium aluminum deuteride, or consists essentially of 60 mol% lithium aluminum hydride and 40 mol% lithium aluminum deuteride, or consists essentially of 55 mol% lithium aluminum hydride and 45 mol% lithium aluminum deuteride. % lithium aluminum hydride, or consists essentially of 50 mol % lithium aluminum hydride and 50 mol % lithium aluminum deuteride, or consists essentially of 45 mol % lithium aluminum hydride and 55 mol % lithium aluminum deuteride, or consists essentially of 40 mol % lithium aluminum hydride and 60 mol % lithium aluminum deuteride, or consists essentially of 35 mol % lithium aluminum hydride and 65 mol % lithium aluminum deuteride, or consists essentially of 30 mol % lithium aluminum hydride and 70 mol % lithium aluminum deuteride, or consists essentially of 25 mol % lithium aluminum hydride and 75 mol % lithium aluminum deuteride, or consists essentially of 20 mol % lithium aluminum hydride and 80 mol % lithium aluminum deuteride, or consists essentially of 15 mol % lithium aluminum by weight.

[0060] According to a specific embodiment, stating that the reducing agent consists essentially of lithium aluminum hydride and lithium aluminum deuteride means that the reducing agent may contain additional components, but the presence of these components does not substantially affect the basic characteristics of the reducing agent (particularly stability and reduction tendency).

[0061] According to a fourth aspect of the present invention, there is provided a pharmaceutical composition comprising a composition as defined according to the first to third aspects of the present invention in combination with a pharmaceutically acceptable excipient.

[0062] The pharmaceutical composition of the present invention comprises a composition of the present invention (according to any one of the first to third aspects of the present invention) in combination with one or more pharmaceutically acceptable excipients. Suitable pharmaceutical compositions can be prepared by technicians, wherein examples of pharmaceutically acceptable excipients include but are not limited to those described in Gennaro et.al., Remmington: The Science and Practice of Pharmacy, 20th edition, Lippincott, Williams and Wilkins, 2000 (particularly part 5: pharmaceutical manufacturing). Suitable excipients are also described in Handbook of Pharmaceutical Excipients, 2nd edition; A. Wade and PJ Weller, American Pharmaceutical Association, Washington, The Pharmaceutical Press, London, 1994.

[0063] Pharmaceutical compositions of the present invention can be compressed into solid dosage units, such as tablets, or processed into capsules or suppositories. Compounds can also be prepared into the form of solutions, suspensions, emulsions or sprays using pharmaceutically suitable liquids. In order to prepare dosage units (including tablets), conventional additives such as fillers, coloring agents, polymer binders, etc. are contemplated. Typically, any pharmaceutically acceptable additive can be used.

[0064] Suitable fillers with which the pharmaceutical composition can be prepared and administered include lactose, starch, cellulose and its derivatives, etc., or mixtures thereof used in suitable amounts. For parenteral administration, aqueous suspensions, isotonic saline solutions and sterile injectable solutions containing pharmaceutically acceptable dispersants and / or wetting agents, such as propylene glycol or butylene glycol, can be used.

[0065] The present invention also provides a pharmaceutical composition of the present invention in combination with packaging material suitable for use with the composition, said packaging material comprising instructions for use of the pharmaceutical composition.

[0066] The compositions of the present invention can be used in therapy and can be administered to a patient in need thereof. As used herein, the term "patient" preferably refers to a human patient, but may also refer to domestic mammals. The term does not include laboratory mammals.

[0067] According to the sixth aspect of the present invention, a composition as defined in any one of the first to fourth aspects is provided for use in a method for treating a patient's mental cognitive disorder. The seventh aspect of the present invention provides a method for treating a mental cognitive disorder, comprising administering a composition as defined in any one of the first to fourth aspects to a patient in need thereof, and the eighth aspect provides the use of a composition as defined in any one of the first to fourth aspects in the preparation of a medicament for use in a method for treating a patient's mental cognitive disorder.

[0068] The term mental cognitive disorder as used herein includes the mental disorder that may be associated with one or more cognitive impairments. The term "mental disorder" as used herein is a clinically significant behavioral or psychological syndrome or pattern that occurs in an individual and is associated with current pain (e.g., pain symptoms) or disability (i.e., the damage in one or more important functional areas) or with a significantly increased risk of suffering death, pain, disability or important freedom loss.

[0069] The diagnostic criteria for the psychiatric disorders and psychotic cognitive disorders referred to herein are provided in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, (DSM-5), the contents of which are incorporated herein by reference.

[0070] As used herein, the term "obsessive-compulsive disorder" is defined as the presence of obsessions or compulsions, but usually both. The symptoms can lead to significant functional impairment and / or distress. Obsessions are defined as unwanted, intrusive thoughts, images, or impulses that repeatedly enter a person's mind. Compulsions are repetitive behaviors or mental behaviors that a person feels driven to perform. Typically, obsessive-compulsive disorder (OCD) manifests as one or more obsessions that drive compulsions. For example, an obsession with germs may drive a compulsion to clean. Compulsions can be overt and observable by others, such as checking if a door is locked, or covert mental behaviors that cannot be observed, such as repeating a phrase in a person's mind.

[0071] As used herein, the term "depressive disorder" includes major depressive disorder, persistent depressive disorder, bipolar disorder, bipolar depression, and depression in terminally ill patients.

[0072] As used herein, the term "major depressive disorder" (MDD, also referred to as major depression or clinical depression) is defined as the presence of five or more of the following symptoms most of the day, nearly every day, over a period of two weeks or longer (also referred to herein as a "major depressive episode"):

[0073] Low mood, such as feeling sad, empty, or tearful (in children and adolescents, low mood may manifest as persistent irritability);

[0074] Significantly decreased interest or pleasure in all or most activities;

[0075] Significant weight loss, weight gain, or decreased or increased appetite when not eating (in children, failure to gain weight as expected);

[0076] Insomnia or increased desire to sleep;

[0077] Restlessness or slowness of behavior that is observable by others;

[0078] Fatigue or loss of energy;

[0079] Feelings of worthlessness, or excessive or inappropriate guilt;

[0080] Difficulty making decisions, or trouble thinking or concentrating;

[0081] Recurrent thoughts of death or suicide, or suicide attempts.

[0082] At least one symptom must be low mood or loss of interest or pleasure.

[0083] Persistent depressive disorder, also known as dysthymia, is defined as patients who exhibit both of the following characteristics:

[0084] A. Depressed mood most of the day, nearly every day, for at least 2 years. Children and adolescents may have irritable moods for at least 1 year.

[0085] B. When depressed, a person experiences at least two of the following symptoms:

[0086] Overeating or lack of appetite.

[0087] Sleeping too much or having trouble sleeping.

[0088] Fatigue and lack of energy.

[0089] ·Poor self-esteem.

[0090] Difficulty concentrating or making decisions.

[0091] As used herein, the term "treatment-resistant depression" describes MDD that has failed to achieve an adequate response to adequate treatment with standard of care therapies.

[0092] As used herein, "bipolar disorder," also known as manic-depressive illness, is a disorder that causes abnormal changes in mood, energy, activity level, and the ability to perform daily tasks.

[0093] There are two defined subtypes of bipolar disorder; all of which involve marked changes in mood, energy, and activity levels. These moods range from extremely "up," euphoric, and energetic behavior (called manic episodes, and defined further below) to very sad, "down," or hopeless periods (called depressive episodes). Less severe manic periods are called hypomanic episodes.

[0094] Bipolar I disorder - defined as a manic episode lasting at least 7 days, or defined as manic symptoms so severe that the person requires immediate hospital care. Often, a depressive episode also occurs, usually lasting at least 2 weeks. Depressive episodes with mixed features (having both depressive and manic symptoms) are also possible.

[0095] Bipolar II disorder - defined as a pattern of depressive episodes and hypomanic episodes, but not the full manic episodes described above.

[0096] As used herein, "bipolar depression" is defined as an individual experiencing depressive symptoms with a preceding or coexisting episode of manic symptoms, but who does not meet clinical criteria for bipolar disorder.

[0097] As used herein, the term "anxiety disorder" includes generalized anxiety disorder, phobias, panic disorder, social anxiety disorder, and post-traumatic stress disorder.

[0098] As used herein, "generalized anxiety disorder" (GAD) refers to a chronic disorder characterized by long-lasting anxiety that is not focused on any one goal or situation. Those suffering from GAD experience non-specific persistent fears and worries, and become overly concerned with daily affairs. GAD is characterized by chronic excessive worrying, accompanied by three or more of the following symptoms: restlessness, fatigue, problems concentrating, irritability, muscle tension, and sleep disturbances.

[0099] A phobia is defined as a persistent fear of an object or situation that the affected person will go to great lengths to avoid, usually out of proportion to the actual danger posed. If the phobic object or situation cannot be completely avoided, the affected person experiences marked distress and it significantly interferes with social or occupational activities.

[0100] Patients with "panic disorder" are defined as those who experience one or more brief episodes of intense terror and apprehension (also called panic attacks), often characterized by trembling, shaking, confusion, dizziness, nausea and / or difficulty breathing. A panic attack is defined as sudden onset of fear or discomfort that reaches a peak in less than ten minutes.

[0101] Social anxiety disorder is defined as an intense fear and avoidance of negative public scrutiny, public embarrassment, humiliation, or social interaction. Social anxiety often manifests with specific physical symptoms, including blushing, sweating, and difficulty speaking.

[0102] Post-traumatic stress disorder (PTSD) is an anxiety disorder caused by traumatic experiences. Post-traumatic stress can be caused by extreme situations such as combat, natural disasters, rape, hostage situations, child abuse, bullying, or even serious accidents. Common symptoms include hypervigilance, flashbacks, avoidance behavior, anxiety, anger, and depression.

[0103] As used herein, the term "substance abuse" refers to a patterned use of drugs in which a user consumes such substances in amounts or in methods that are harmful to themselves or others.

[0104] As used herein, the term "avolition disorder" refers to a disorder that includes as a symptom a reduced motivation to initiate and perform self-directed purposeful activities.

[0105] In preferred embodiments of the sixth to eighth aspects of the present invention, the psychiatric cognitive disorder is selected from (i) obsessive compulsive disorder, (ii) depressive disorder, (iii) anxiety disorder, (iv) substance abuse and (v) amotivational disorder.

[0106] According to specific embodiments of the sixth to eighth aspects of the present invention, the depressive disorder is major depressive disorder. According to still more specific embodiments, the major depressive disorder is treatment-resistant major depressive disorder.

[0107] Compositions comprising partially deuterated N,N-dimethyltryptamine compounds of the present invention can be synthesized according to the reaction schemes (synthetic schemes) provided in Schemes 1 and 2 below. The chemistry described in the schemes is reported by PE Morris and C Chiao (Journal of Labelled Compounds And Radiopharmaceuticals, Vol. XXXIII, No. 6, 455-465 (1993)). Compositions comprising partially deuterated N,N-dimethyltryptamine compounds of the present invention can also be synthesized according to the synthetic schemes depicted in Schemes 3 and Example 4 below.

[0108] The relative proportion of N,N-dimethyltryptamine relative to deuterated N,N-dimethyltryptamine compounds and partially deuterated N,N-dimethyltryptamine compounds can be controlled by changing the ratio of lithium aluminum hydride and lithium aluminum deuteride in the reducing agent. The relative proportion can be further changed by adding one or more of N,N-dimethyltryptamine, α,α-dideutero-N,N-dimethyltryptamine and α,α,β,β-tetradeutero-N,N-dimethyltryptamine to the composition described above.

[0109] A particular advantage of the present invention (especially but not limited to the compositions obtainable according to the second and third aspects of the invention and the method of the ninth aspect thereof) is that the reduction described in these aspects of the invention allows particularly high purity to be obtained without the need for subsequent chromatographic purification (e.g., column chromatography), thereby increasing the efficiency with which the compositions of the invention can be prepared. In addition, the ability to avoid the use of chromatography to achieve high purity makes scale-up more efficient and therefore more cost-effective.

[0110] If desired, identification of the composition resulting from the reduction steps in Schemes 1 and 2 (which represent specific embodiments of the second and third aspects of the invention) may be achieved by chromatographic separation of the components of the mixture by conventional means at the disposal of the skilled person in combination with spectroscopic and / or mass spectrometric analysis.

[0111]

[0112] Solution 1

[0113]

[0114] Solution 2

[0115] The alternative composition of the present invention is obtained by mixing N,N-dimethyltryptamine (obtainable by Scheme 1 or Scheme 2 when the reducing agent is only lithium aluminum hydride) with a deuterated N,N-dimethyltryptamine compound (obtainable by Scheme 1 or Scheme 2 when the reducing agent is only lithium aluminum hydride).

[0116] The composition described above can be further improved by adding one or more deuterated or partially deuterated N,N-dimethyltryptamine compounds. The stock of such deuterated or partially deuterated N,N-dimethyltryptamine compounds can be obtained, for example, from the above-mentioned chromatographic separation. In this way, for example, the compound of the tenth aspect of the present invention can be obtained. According to a specific embodiment of the tenth aspect, the compound is selected from α, β, β-trideuterated-N,N-dimethyltryptamine, α, β-dideuterated-N,N-dimethyltryptamine and α-deuterated-N,N-dimethyltryptamine.

[0117] Although identification of the composition resulting from the reduction described herein can be achieved by chromatographic separation of the components of the mixture in combination with spectroscopic and / or mass spectrometric analysis, a particular benefit of the present invention is that, according to specific embodiments, this may not be necessary. This is because, beyond the purity achievable according to the present invention, we have recognized as described above that there is a quantifiable relationship between the degree of deuteration (or in other words, the amount or proportion of deuterium in the N,N-dimethyltryptamine compound in the composition of the present invention) and the metabolic half-life of the resulting composition. The degree of deuteration can be controlled by the amount of deuterium-containing reducing agent used in the method of the present invention, by which (according to a specific embodiment) the composition of the present invention can be obtained, thereby controlling the enhancement of the metabolic half-life of the parent compound (undeuterated N,N-dimethyltryptamine) in a predictable manner.

[0118] In particular, as in Example 4 and related Figure 2 and 3 As described in, we have demonstrated that increasing deuterium enrichment at the α-carbon of N,N-dimethyltryptamine increases metabolic stability, resulting in reduced clearance and longer half-life. A linear relationship exists between molecular weight and half-life, particularly when the feed reductant used to produce the composition containing deuterium-enriched N,N-dimethyltryptamine of the present invention comprises LiAlH4 and LiAlD4 in a ratio of about 1:2.5 to about 2.5:1.

[0119] Compositions of this type constitute specific embodiments of the first aspect of the present invention. According to these specific embodiments, the composition consists essentially of a mixture of N,N-dimethyltryptamine and one or both of α-deuterated-N,N-dimethyltryptamine and α,α-dideuterated-N,N-dimethyltryptamine, optionally in the form of a pharmaceutically acceptable salt, wherein the average molecular weight of the N,N-dimethyltryptamine, α-deuterated-N,N-dimethyltryptamine and α,α-dideuterated-N,N-dimethyltryptamine present in the composition is 188.28 to 190.28.

[0120] The average molecular weight as used herein refers to the weighted average of the molecular weights of N,N-dimethyltryptamine and one or both of α-deuterated-N,N-dimethyltryptamine and α,α-dideuterated-N,N-dimethyltryptamine, as measured by a suitable mass spectrometry technique (e.g., LC-MS SIM (selected ion monitoring)), ignoring any weight contribution caused by the formation of pharmaceutically acceptable salts where applicable.

[0121] It should be understood that one skilled in the art can achieve providing a composition having such a specific average molecular weight through the teachings herein, particularly by adjusting the relative proportions of lithium aluminum hydride and lithium aluminum deuteride in the reduction described herein.

[0122] In this regard, stating that the composition consists essentially of a mixture of N,N-dimethyltryptamine and one or both of α-deuterated-N,N-dimethyltryptamine and α,α-dideuterated-N,N-dimethyltryptamine means that the composition may contain additional components other than these, but the presence of such additional components will not substantially affect the basic characteristics of the composition. In particular, the composition will not contain substantial amounts of other pharmaceutically active compounds (including other N,N-dimethyltryptamine compounds). Therefore, there is no substantial amount of other deuterated N,N-dimethyltryptamine compounds, particularly β-deuterated-N,N-dimethyltryptamine compounds and β,β-dideuterated-N,N-dimethyltryptamine compounds, such as β-deuterated-N,N-dimethyltryptamine and β,β-dideuterated-N,N-dimethyltryptamine and β-deuterated-N,N-dimethyltryptamine and β,β-dideuterated-N,N-dimethyltryptamine, having one or two deuterium atoms replacing the hydrogen atoms at the α position, respectively, in the composition of such embodiments.

[0123] In other words, and alternatively, the composition according to these specific embodiments constitutes a drug substance comprising a biologically active ingredient consisting essentially of a mixture of N,N-dimethyltryptamine and one or more of α-deuterated-N,N-dimethyltryptamine and α,α-dideuterated-N,N-dimethyltryptamine, wherein the biologically active ingredient has an average molecular weight of 188.28 to 190.28, and wherein the drug substance is optionally in the form of a pharmaceutically acceptable salt.

[0124] It should be understood that the composition according to these embodiments comprises one or more of α-deuterated-N,N-dimethyltryptamine and α,α-dideuterated-N,N-dimethyltryptamine in an amount greater than the amount in isotopically non-enriched N,N-dimethyltryptamine. It will also be understood that the greater the ratio of α-deuterated-N,N-dimethyltryptamine and α,α-dideuterated-N,N-dimethyltryptamine in these embodiments, the higher the average molecular weight of the composition.

[0125] According to a more specific embodiment, the average molecular weight of N,N-dimethyltryptamine, α-deuterated-N,N-dimethyltryptamine and α,α-dideuterated-N,N-dimethyltryptamine present in the composition is 188.9 to 189.7, such as 188.90 to 189.70.

[0126] Still more specific embodiments according to the specific embodiments described herein include compositions wherein the average molecular weight of N,N-dimethyltryptamine, α-deuterated-N,N-dimethyltryptamine and α,α-dideuterated-N,N-dimethyltryptamine present in the composition is 188.9 to 189.7, for example 188.90 to 189.70, the composition is optionally in the form of a pharmaceutically acceptable salt, whereby it will be understood that the N,N-dimethyltryptamine, α-deuterated-N,N-dimethyltryptamine and α,α-dideuterated-N,N-dimethyltryptamine present in the composition are present in the form of a pharmaceutically acceptable salt. Such salts may be as described elsewhere herein, and according to more specific embodiments, the composition is in the form of a fumarate.

[0127] Each patent and non-patent reference mentioned herein is hereby incorporated by reference in its entirety, as if each reference were set forth in its entirety herein.

[0128] The present invention may be further understood with reference to the following non-limiting clauses and the following examples:

[0129] 1. A composition comprising two or more compounds selected from N,N-dimethyltryptamine, deuterated N,N-dimethyltryptamine and partially deuterated N,N-dimethyltryptamine.

[0130] 2. The composition of claim 1, comprising a combination of N,N-dimethyltryptamine and 2% or more by weight of one or more deuterated or partially deuterated N,N-dimethyltryptamine compounds, wherein the deuterated N,N-dimethyltryptamine compound is substituted with two deuterium atoms at the α position, and the partially deuterated N,N-dimethyltryptamine compound is an N,N-dimethyltryptamine compound having one hydrogen atom and one deuterium atom at the α position.

[0131] 3. The composition of clause 1 or 2, wherein the deuterated N,N-dimethyltryptamine compound is selected from α,α-dideutero-N,N-dimethyltryptamine and α,α,β,β-tetradeutero-N,N-dimethyltryptamine.

[0132] 4. The composition of clause 3, comprising 2% by weight or more of α,α,β,β-tetradeuterated-N,N-dimethyltryptamine.

[0133] 5. The composition of clause 3 or 4, comprising 2% by weight or more of α,α-dideutero-N,N-dimethyltryptamine.

[0134] 6. The composition of any one of clauses 1 to 5, comprising one or more partially deuterated N,N-dimethyltryptamine compounds selected from α,β,β-trideuterated-N,N-dimethyltryptamine, α,β-dideuterated-N,N-dimethyltryptamine and α-deuterated-N,N-dimethyltryptamine.

[0135] 7. The composition of clause 6, wherein the partially deuterated N,N-dimethyltryptamine compound is α-deuterated-N,N-dimethyltryptamine.

[0136] 8. The composition of any one of clauses 1 to 7, wherein the one or more partially deuterated N,N-dimethyltryptamine compounds comprise up to 50% by weight of the total composition.

[0137] 9. The composition of any one of clauses 1 to 8 comprising 5% to 95% by weight of N,N-dimethyltryptamine.

[0138] 10. The composition of any one of clauses 1 to 9 comprising 5% to 95% by weight of a deuterated N,N-dimethyltryptamine compound selected from α,α-dideutero-N,N-dimethyltryptamine and α,α,β,β-tetradeutero-N,N-dimethyltryptamine.

[0139] 11. A composition obtainable by reducing 2-(3-indolyl)-N,N-dimethylglyoxylamide with a reducing agent consisting essentially of up to 90% by weight of lithium aluminum hydride and 10% or more by weight of lithium aluminum deuteride.

[0140] 12. A composition obtainable by reducing 2-(3-indolyl)-N,N-dimethylacetamide with a reducing agent consisting essentially of up to 90% by weight of lithium aluminum hydride and 10% or more by weight of lithium aluminum deuteride.

[0141] 13. The composition of any one of clauses 1 to 12, for use in treating a psychotic disorder or a psychocognitive disorder in a patient.

[0142] 14. A composition for use according to clause 13, wherein the psychiatric disorder or cognitive disorder is selected from (i) obsessive-compulsive disorder, (ii) depressive disorder, (iii) anxiety disorder, (iv) substance abuse and (v) amotivational disorder.

[0143] 15. A compound selected from the group consisting of α,β,β-trideuterated-N,N-dimethyltryptamine, α,β-dideuterated-N,N-dimethyltryptamine and α-deuterated-N,N-dimethyltryptamine. Example

[0144] Embodiment 1:

[0145] 2-(3-Indolyl)-N,N-dimethylacetamide was synthesized as described in Morris and Chiao (1993), Journal of Labelled Compounds and Radiopharmaceuticals, Vol. XXXIII, No. 6. 0.063 g of LiAlH4 and 0.278 g of LiAlD4 (molar ratio of LiAlH4:LiAlD4 was 20:80) were suspended in 25 ml of anhydrous Et2O while magnetically stirring. 0.785 g of 2-(3-indolyl)-N,N-dimethylacetamide was dissolved in 300 ml and added dropwise to the stirred suspension. The reagent was heated at reflux for 3 hours, then cooled in an ice bath and quenched dropwise with water. The resulting mixture was filtered, dried, and the solvent was removed under vacuum to obtain approximately 0.5 g of a composition consisting of 3 mol% N,N-dimethyltryptamine, 28 mol% α-deuterated-N,N-dimethyltryptamine, and 69 mol% α,α-dideuterated-N,N-dimethyltryptamine.

[0146] Embodiment 2:

[0147] 0.173 g of LiAlH4 and 0.156 g of LiAlD4 (molar ratio of LiAlH4:LiAlD4 is 55:45) are suspended in 25 ml of anhydrous Et2O while stirring magnetically. 0.785 g of 2-(3-indolyl)-N,N-dimethylacetamide is dissolved in 300 ml and added dropwise to the stirred suspension. The reagent is heated under reflux for 3 hours, then cooled in an ice bath and quenched with water dropwise. The resulting mixture is filtered, dried, and the solvent is removed under vacuum to obtain approximately 0.5 g of a composition consisting of 24 mol% of N,N-dimethyltryptamine, 50 mol% of α-deuterated-N,N-dimethyltryptamine, and 26 mol% of α,α-dideuterated-N,N-dimethyltryptamine.

[0148] Embodiment 3:

[0149] 0.293 g of LiAlH4 and 0.035 g of LiAlD4 (molar ratio of LiAlH4:LiAlD4 is 90:10) are suspended in 25 ml of anhydrous Et2O while magnetically stirring. 0.785 g of 2-(3-indolyl)-N,N-dimethylacetamide is dissolved in 300 ml and added dropwise to the stirred suspension. The reagent is heated under reflux for 3 hours, then cooled in an ice bath and quenched with water dropwise. The resulting mixture is filtered, dried, and the solvent is removed under vacuum to obtain approximately 0.5 g of a composition consisting of 76 mol % of N,N-dimethyltryptamine, 22 mol % of α-deuterated-N,N-dimethyltryptamine, and 2 mol % of α,α-dideuterated-N,N-dimethyltryptamine.

[0150] Example 4: Evaluation of the Intrinsic Clearance of Deuterated DMT Analog Blends Relative to DMT in Vitro Using Human Hepatocytes

[0151] In vitro determination of intrinsic clearance is a valuable model for predicting in vivo hepatic clearance. The liver is the major organ for drug metabolism in vivo and contains both Phase I and Phase II drug metabolizing enzymes present in intact cells.

[0152] Synthesis of samples

[0153] N,N-DMT 220.9 g (as the free base) was prepared as N,N-DMT fumarate salt using the chemistry depicted in Scheme 3. An additional 4-6 g of a mixture of six partial deuterations was also produced using modified conditions.

[0154]

[0155] Solution 3

[0156] Synthesis of DMT

[0157] Stage 1: Coupling of indole-3-acetic acid and dimethylamine

[0158] Indole-3-acetic acid (257.0 g, 1.467 mol), hydroxybenzotriazole (HOBt, ~20% moisture) (297.3 g, 1.760 mol) and dichloromethane (2313 mL) were added to a 5 L vessel under N2 to give a milky white suspension. Then, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC.HCl, 337.5 g, 1.760 mol) was added portionwise over 5 minutes at 16-22°C. The reaction mixture was stirred at ambient temperature for 2 hours, after which 2M dimethylamine in THF (1100 mL, 2.200 mol) was added dropwise over 20 minutes at 20-30°C. The resulting solution was stirred at ambient temperature for 1 hour, at which time HPLC indicated 1.1% indole-3-acetic acid and 98.1% of the desired product (referred to as stage 1). Then, 10% K2CO3 (1285mL) was added to the reaction mixture and stirred for 5 minutes. The layers were separated and the upper aqueous layer was extracted with dichloromethane (643mL×2). The organic extracts were combined and washed with saturated brine (643mL). Then, the organic extracts were dried over MgSO4, filtered and concentrated in vacuo at 45°C. This gave 303.1g of crude stage 1 as an off-white sticky solid. Then, at 50°C, in tert-butyl methyl ether (TBME, 2570mL), the crude material was slurried for 2 hours, then cooled to ambient temperature, filtered and washed with TBME (514mL×2). Afterwards, the filter cake was vacuum dried at 50°C to give stage 1 266.2g (yield = 90%) as an off-white solid, with a purity of 98.5% as measured by HPLC and a purity of >95% as measured by NMR.

[0159] Phase 2: Preparation of DMT

[0160] Under N2, stage 1 (272.5 g, 1.347 mol) and tetrahydrofuran (THF, 1363 mL) were added to a 5 L container to give an off-white suspension. Then, 2.4 M LiAlH4 (505.3 mL, 1.213 mol) in THF was added dropwise at 20-56°C over 35 minutes to give an amber solution. The solution was heated to 60°C for 2 hours, where HPLC indicated stage 1ND, the desired product (called stage 2, 92.5%), impurity 1 (2.6%), impurity 2 (1.9%). The complete reaction mixture was cooled to ambient temperature and then added dropwise to a solution of 25% Rochelle's salts (aq) (2725 mL) at 20-30°C over 30 minutes. The resulting milky suspension was stirred at 20-25°C for 1 hour, after which the layers were separated and the upper organic layer was washed with saturated brine (681 mL). Then. The organic layer was dried over MgSO4, filtered and concentrated in vacuo at 45°C. The resulting crude oil was azeotroped with ethanol (545 mL x 2). This gave 234.6 g (yield = 92%) of stage 2 with a purity of 95.0% by HPLC and >95% by NMR.

[0161] Stage 3a(i)-(iii): Preparation of seed crystals of DMT fumarate

[0162] (i) Stage 2 (100 mg) was taken up in 8 volumes of isopropyl acetate and heated to 50° C., after which a solution of fumaric acid (1 equivalent) in ethanol was added. The flask was then aged at 50° C. for 1 hour, then cooled to room temperature and stirred overnight to give a white suspension. The solid was isolated by filtration and dried at 50° C. for 4 hours to give 161 mg of product (yield > 99%). The purity was 99.5% by HPLC and > 95% by NMR.

[0163] (ii) Substituting isopropyl acetate with isopropyl alcohol in method (i) gave a white suspension after stirring overnight. The solid was isolated by filtration and dried at 50° C. for 4 hours to give 168 mg of the product (yield>99%). The purity was 99.8% by HPLC and >95% by NMR.

[0164] Substituting tetrahydrofuran for isopropyl acetate in method (i) gave a white suspension after stirring overnight. The solid was isolated by filtration and dried at 50°C for 4 hours to give 161 mg of the product (yield>99%). The purity was 99.4% by HPLC and>95% by NMR.

[0165] Analysis by X-ray powder diffraction showed that the product of each of methods 9i) to (iii) was identical, which was labeled Pattern A.

[0166] Phase 3b: Preparation of DMT Fumarate

[0167] To a 5 L flange flask under N2 was added a solution of fumaric acid (152.7 g, 1.315 mol) and stage 2 (248.2 g, 1.315 mol) in ethanol (2928 mL). The mixture was heated to 75°C to give a dark brown solution. The solution was polish filtered into a preheated (80°C) 5 L jacketed vessel. The solution was then cooled to 70°C and seeded with pattern A (0.1 wt%), the seeds were allowed to mature for 30 minutes, and then cooled to 0°C at a rate of 5°C / hour. After stirring at 0°C for an additional 4 hours, the batch was filtered and washed with cold ethanol (496 mL x 2) and then dried at 50°C overnight. This gave 312.4 g (yield = 78%) of stage 3 with a purity of 99.9% by HPLC and >95% by NMR. XRPD: pattern A.

[0168] Synthesis of deuterated mixtures of DMT compounds

[0169] A modified synthesis using a solid LiAlH4 / LiAlD4 mixture in stage 2 was employed, using 1.8 equivalents of LiAlH4 / LiAlD4 relative to 0.9 equivalents using the above method for undeuterated DMT.

[0170] Six deuteration reactions were performed.

[0171] Representative synthesis of deuterated mixtures of DMT compounds (using 1:1 LiAlH4:LiAlD4)

[0172] Under N2, LiAlH4 (1.013g, 26.7mmol), LiAlD4 (1.120g, 26.7mmol) and THF (100mL) were added to a 250mL 3-necked flask. The resulting suspension was stirred for 30 minutes, after which stage 1 (6g, 29.666mmol) was added in batches at 20-40°C over 15 minutes. The reaction mixture was then heated to reflux (66°C) for 2 hours, with HPLC indicating that no stage 1 remained. The mixture was cooled to 0°C and quenched with 25% Rochelle salt (aq) (120mL) at <30°C over 30 minutes. The resulting milky suspension was stirred for 1 hour and then separated. The lower aqueous layer was removed, and the upper organic layer was washed with saturated brine (30ml). The organic layer was then dried over MgSO4, filtered and concentrated in vacuo. This gave 4.3g of crude material. The crude material was then taken up in ethanol (52 mL) and fumaric acid (2.66 g, 22.917 mmol) was added before heating to 75 °C. The resulting solution was cooled to ambient temperature overnight and then further cooled to 0-5 °C for 1 hour. The solid was isolated by filtration and washed with cold ethanol (6.5 mL x 2). The filter cake was dried overnight at 50 °C to give 5.7 g (yield = 63%) of product with a purity of 99.9% by HPLC and >95% by NMR.

[0173] Assessment of the degree of deuteration

[0174] This is achieved by LCMS-SIM (SIM = Single Ion Monitoring), which obtains individual ion counts of the respective masses of the three deuterated N,N-dimethyltryptamine compounds (N,N-dimethyltryptamine (D0), α-deuterated-N,N-dimethyltryptamine (D1) and α,α-dideuterated-N,N-dimethyltryptamine (D2)) at the retention time of N,N-dimethyltryptamine. The percentage of each component is then calculated from these ion counts.

[0175] For example, %D0 = [D0 / (D0+D1+D2)] x 100.

[0176]

[0177]

[0178]

[0179] MS-SIM range is target mass ±0.1 m / z

[0180] The data for the six deuterated reactions are listed in Table 1 below:

[0181]

[0182]

[0183] In vitro intrinsic clearance of DMT (SPL026) and a blend of six deuterated compounds

[0184] In vitro determination of intrinsic clearance is a valuable model for predicting in vivo hepatic clearance. The liver is the major organ for drug metabolism in vivo and contains both Phase I and Phase II drug metabolizing enzymes present in intact cells.

[0185] Purpose

[0186] To evaluate the in vitro intrinsic clearance of a blend of deuterated DMT analogs relative to DMT using human hepatocytes.

[0187] Experimental Description

[0188] The in vitro intrinsic clearance of DMT and six deuterated analogs was studied using human (mixed sex) hepatocytes (545,000 cells / ml) collected from 10 donors.

[0189] All test compounds and sumatriptan, 5-HT, benzylamine controls were used at a concentration of 5 μM. This concentration was chosen to maximize the signal-to-noise ratio while remaining below the Michaelis constant (Km) for monoamine oxidase (MAO). Diltiazem and diclofenac controls were used at a laboratory validated concentration of 1 μM.

[0190] The test compound was mixed with the hepatocyte suspension in a 96-well plate and incubated at 37°C for up to 60 minutes. The suspension was stirred continuously. At 7 time points, small aliquots were taken and the test compound / blend concentration was measured by LC-MS / MS. The time points measured were 2, 4, 8, 15, 30, 45 and 60 minutes.

[0191] The following LC-MS / MS conditions were used for analysis:

[0192] Instrument: Thermo TSQ Quantiva with Thermo Vanquish UPLC system

[0193] Column: Luna Omega 2.1x50mm 2.6μm

[0194] Solvent A: H2O + 0.1% formic acid

[0195] Solvent B: Acetonitrile + 0.1% formic acid

[0196] Flow rate: 0.8ml / min

[0197] Injection volume: 1μl

[0198] Column temperature: 65℃

[0199] gradient:

[0200]

[0201] MS parameters:

[0202] Positive ion spray voltage: 4000V

[0203] Evaporator temperature: 450℃

[0204] Ion transfer tube temperature: 365°C

[0205] Sheath gas: 54

[0206] Auxiliary gas: 17

[0207] Purge gas: 1

[0208] Dwell time: 8ms

[0209] MRM conversion:

[0210] D0 = mass-to-charge ratio 189.14>58.16.

[0211] D1 = mass-to-charge ratio 190.14>59.17.

[0212] D2 = mass-to-charge ratio 191.14>60.17.

[0213] MRM transitions were determined from preliminary analysis of DMT samples containing no deuterium (for the D0 transition) or high levels of D1 or D2 deuteration (for the D1 and D2 transitions, respectively).

[0214] Then, intrinsic clearance (CLint) and half-life (t1 / 2) are calculated using the obtained concentration-time curve. For this reason, the MS peak area or MS peak area / IS response of each analyte is plotted on a natural logarithmic scale on the y-axis relative to the sampling time (min) on the x-axis. The slope of this line is the elimination rate constant. This is converted to half-life by -ln(2) / slope. Intrinsic clearance is calculated by slope / elimination rate constant, and the formula is CLint=(-1000*slope) / cell density in 1E6 cells / ml, resulting in units of microliters / minute / million cells.

[0215] result

[0216] The intrinsic clearance and half-life values ​​for DMT and the above six deuterated mixtures were calculated. These data were weighted according to the ratio of D0, D1 and D2 to obtain the overall intrinsic clearance and half-life values ​​for each compound mixture (Table 2).

[0217] Table 2 In vitro intrinsic clearance and calculated half-life of DMT and six deuterated mixtures

[0218]

[0219]

[0220] Using regression analysis, a linear model was fitted to the data, which revealed that deuterium enrichment at the α-carbon of DMT linearly decreased intrinsic clearance with increasing molecular weight (MW), thus enabling the preparation of DMT drug substances with accurately predictable half-lives within the identified range.

[0221] The greatest change was seen with mixture 1 containing 96.6% D2-DMT, with intrinsic clearance almost halved compared to undeuterated DMT ( Figure 3 ), the half-life is almost doubled ( Figure 2 The deuterated intermediate blends (Mixtures 2 to 5) decreased intrinsic clearance in a molecular weight-dependent manner ( Figure 3 ).

[0222] in conclusion

[0223] These data demonstrate that increasing deuterium enrichment at the α-carbon of DMT improves metabolic stability, resulting in reduced clearance and longer half-life. A linear relationship exists between MW and half-life, particularly when the feed reductant used to produce a drug substance containing deuterium-enriched DMT by the method of the present invention comprises LiAlH4 and LiAlD4 in a ratio of 1:2.5 to 2.5:1.

Claims

1. A composition comprising: (a) an α,α-dideutero-N,N-dimethyltryptamine compound or a pharmaceutically acceptable salt thereof; (b) an α-protonated, α-deutero-N,N-dimethyltryptamine compound or a pharmaceutically acceptable salt thereof; and (c) N,N-dimethyltryptamine or a pharmaceutically acceptable salt thereof; The composition comprises 50% by weight or more of an α,α-dideutero-N,N-dimethyltryptamine compound or a pharmaceutically acceptable salt thereof, and an α-protonated, α-deutero-N,N-dimethyltryptamine compound or a pharmaceutically acceptable salt thereof.

2. The composition of claim 1, consisting essentially of: a) α,α-dideutero-N,N-dimethyltryptamine or a pharmaceutically acceptable salt thereof; b) α-protonated, α-deuterated-N,N-dimethyltryptamine or a pharmaceutically acceptable salt thereof; and c) N,N-dimethyltryptamine or a pharmaceutically acceptable salt thereof; The average molecular weight of α-protonated, α-deuterated-N,N-dimethyltryptamine, α,α-dideuterated-N,N-dimethyltryptamine and N,N-dimethyltryptamine present in the composition is 188.90 to 190.

28.

3. The composition of claim 1 or claim 2, comprising 60% by weight or more of an α,α-dideutero-N,N-dimethyltryptamine compound or a pharmaceutically acceptable salt thereof, and an α-protonated, α-deutero-N,N-dimethyltryptamine compound or a pharmaceutically acceptable salt thereof.

4. The composition of claim 1 or claim 2, wherein the α,α-dideutero-N,N-dimethyltryptamine compound is α,α-dideutero-N,N-dimethyltryptamine or a pharmaceutically acceptable salt thereof.

5. The composition of claim 3, wherein the α,α-dideutero-N,N-dimethyltryptamine compound is α,α-dideutero-N,N-dimethyltryptamine or a pharmaceutically acceptable salt thereof.

6. The composition of claim 1 or claim 5, comprising an α-protonated, α-deuterated-N,N-dimethyltryptamine compound selected from the group consisting of α,β,β-trideuterated-N,N-dimethyltryptamine, α,β-dideuterated-N,N-dimethyltryptamine and α-protonated, α-deuterated-N,N-dimethyltryptamine and pharmaceutically acceptable salts thereof.

7. The composition of claim 3, comprising an α-protonated, α-deuterated-N,N-dimethyltryptamine compound selected from the group consisting of α,β,β-trideuterated-N,N-dimethyltryptamine, α,β-dideuterated-N,N-dimethyltryptamine and α-protonated, α-deuterated-N,N-dimethyltryptamine and pharmaceutically acceptable salts thereof.

8. The composition of claim 4, comprising an α-protonated, α-deuterated-N,N-dimethyltryptamine compound selected from the group consisting of α,β,β-trideuterated-N,N-dimethyltryptamine, α,β-dideuterated-N,N-dimethyltryptamine and α-protonated, α-deuterated-N,N-dimethyltryptamine and pharmaceutically acceptable salts thereof.

9. The composition of any one of claims 1, 2, 5, 7 and 8, comprising α-protonated, α-deuterated-N,N-dimethyltryptamine or a pharmaceutically acceptable salt thereof.

10. The composition of claim 3, comprising α-protonated, α-deuterated-N,N-dimethyltryptamine or a pharmaceutically acceptable salt thereof.

11. The composition of claim 4, comprising α-protonated, α-deuterated-N,N-dimethyltryptamine or a pharmaceutically acceptable salt thereof.

12. The composition of claim 6, comprising α-protonated, α-deuterated-N,N-dimethyltryptamine or a pharmaceutically acceptable salt thereof.

13. The composition of any one of claims 1 to 2, 5, 7 to 8 and 10 to 12, having an HPLC purity greater than or equal to 99%.

14. The composition of claim 3, having an HPLC purity greater than or equal to 99%.

15. The composition of claim 4, having an HPLC purity greater than or equal to 99%.

16. The composition of claim 6, having an HPLC purity greater than or equal to 99%.

17. The composition of claim 9, having an HPLC purity greater than or equal to 99%.

18. The composition of claim 13, having an HPLC purity greater than or equal to 99.9%.

19. The composition of any one of claims 14 to 17, having an HPLC purity greater than or equal to 99.9%.

20. The composition of any one of claims 1 to 2, 5, 7 to 8, 10 to 12 and 14 to 18, wherein the α-protonated, α-deuterated-N,N-dimethyltryptamine and α,α-dideuterated-N,N-dimethyltryptamine compounds and N,N-dimethyltryptamine are in the form of pharmaceutically acceptable salts.

21. The composition of claim 3, wherein the α-protonated, α-deuterated-N,N-dimethyltryptamine and α,α-dideuterated-N,N-dimethyltryptamine compounds and N,N-dimethyltryptamine are in the form of pharmaceutically acceptable salts.

22. The composition of claim 4, wherein the α-protonated, α-deuterated-N,N-dimethyltryptamine and α,α-dideuterated-N,N-dimethyltryptamine compounds and N,N-dimethyltryptamine are in the form of pharmaceutically acceptable salts.

23. The composition of claim 6, wherein the α-protonated, α-deuterated-N,N-dimethyltryptamine and α,α-dideuterated-N,N-dimethyltryptamine compounds and N,N-dimethyltryptamine are in the form of pharmaceutically acceptable salts.

24. The composition of claim 9, wherein the α-protonated, α-deuterated-N,N-dimethyltryptamine and α,α-dideuterated-N,N-dimethyltryptamine compounds and N,N-dimethyltryptamine are in the form of pharmaceutically acceptable salts.

25. The composition of claim 13, wherein the α-protonated, α-deuterated-N,N-dimethyltryptamine and α,α-dideuterated-N,N-dimethyltryptamine compounds and N,N-dimethyltryptamine are in the form of pharmaceutically acceptable salts.

26. The composition of claim 19, wherein the α-protonated, α-deuterated-N,N-dimethyltryptamine and α,α-dideuterated-N,N-dimethyltryptamine compounds and N,N-dimethyltryptamine are in the form of pharmaceutically acceptable salts.

27. The composition according to claim 20, wherein the pharmaceutically acceptable salt is a fumarate.

28. A composition according to any one of claims 21 to 27, wherein the pharmaceutically acceptable salt is a fumarate salt.

29. The composition of any one of claims 1 to 2, 5, 7 to 8, 10 to 12, 14 to 18 and 21 to 27, wherein the α-protonated, α-deuterated-N,N-dimethyltryptamine and α,α-dideuterated-N,N-dimethyltryptamine compounds and N,N-dimethyltryptamine are in the form of fumarate salts.

30. The composition of claim 3, wherein the α-protonated, α-deuterated-N,N-dimethyltryptamine and α,α-dideuterated-N,N-dimethyltryptamine compounds and N,N-dimethyltryptamine are in the form of fumarate salts.

31. The composition of claim 4, wherein the α-protonated, α-deuterated-N,N-dimethyltryptamine and α,α-dideuterated-N,N-dimethyltryptamine compounds and N,N-dimethyltryptamine are in the form of fumarate salts.

32. The composition of claim 6, wherein the α-protonated, α-deuterated-N,N-dimethyltryptamine and α,α-dideuterated-N,N-dimethyltryptamine compounds and N,N-dimethyltryptamine are in the form of fumarate salts.

33. The composition of claim 9, wherein the α-protonated, α-deuterated-N,N-dimethyltryptamine and α,α-dideuterated-N,N-dimethyltryptamine compounds and N,N-dimethyltryptamine are in the form of fumarate salts.

34. The composition of claim 13, wherein the α-protonated, α-deuterated-N,N-dimethyltryptamine and α,α-dideuterated-N,N-dimethyltryptamine compounds and N,N-dimethyltryptamine are in the form of fumarate salts.

35. The composition of claim 19, wherein the α-protonated, α-deuterated-N,N-dimethyltryptamine and α,α-dideuterated-N,N-dimethyltryptamine compounds and N,N-dimethyltryptamine are in the form of fumarate salts.

36. The composition of claim 20, wherein the α-protonated, α-deuterated-N,N-dimethyltryptamine and α,α-dideuterated-N,N-dimethyltryptamine compounds and N,N-dimethyltryptamine are in the form of fumarate salts.

37. The composition of claim 28, wherein the α-protonated, α-deuterated-N,N-dimethyltryptamine and α,α-dideuterated-N,N-dimethyltryptamine compounds and N,N-dimethyltryptamine are in the form of fumarate salts.

38. A pharmaceutical composition comprising a composition as defined in any one of claims 1 to 37 in combination with a pharmaceutically acceptable excipient.

39. Use of a composition as defined in any one of claims 1 to 37 or a pharmaceutical composition as defined in claim 38 for the preparation of a medicament for treating a psychotic cognitive disorder in a patient.

40. The use of claim 39, wherein the psychiatric cognitive disorder is selected from the group consisting of (i) obsessive compulsive disorder, (ii) depressive disorder, (iii) anxiety disorder, (iv) substance abuse and (v) amotivational disorder.

41. The use of claim 40, wherein the depressive disorder is major depressive disorder.

42. The use of claim 41, wherein the depressive disorder is treatment-resistant depression.

43. Use of a composition as defined in any one of claims 1 to 37 or a pharmaceutical composition as defined in claim 38 for the preparation of a medicament for use in dimethyltryptamine-assisted psychotherapy.

Citation Information

Patent Citations

  • Arylpiperazine modulators of d2 receptors, 5-HT1a receptors, and / or 5-HT2a receptors

    US20100069399A1

  • N-(2-(substituted-naphth-1-yl)ethyl) substituted amide compound, preparation and uses thereof

    US20210077431A1

  • Combination product for the treatment of neurological and / or psychiatric disorders

    WO2019081764A1